Farmak, A.s.

Hameln Pharma Plus Gmbh

Scale Up Laboratory, S.r.o.

Pavel Hradil

Petr Slezar

Martin Grepl

Lubomir Kvapil

Radek Melnicky

Jan Novotny

Roman Gabriel

Vendel Smahovský

Pavol Valachovic

Janka Králová

Ivan Kakalik

Petr Slézar

Radek Melnický

Mathias Dewald

Barbora Dvorakova

Kamil Koristek

Christian Schickaneder

Miroslav Urbasek

Petr Funk

Radim HORÁK

Miroslav URBÁSEK

Lubomír Kvapil

Janka KRÁLOVÁ

Ivan KAKALÍK

The invention relates to the production of zinc trisodium pentetic acid (Zn-DTPA) and to new crystalline forms of said salt.

Crystalline forms of zinc trisodium pentetic acid

The invention relates to a compound which is, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine, which is a selective A2A adenosine receptor agonist in myocardial imaging. The new polymorph of 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine (designated as polymorph E) is characterized by an X-ray diffraction pattern of X-RPD showing the following reflections at 2 Theta=5.8&#xb0;, 12.3&#xb0;, 15.9&#xb0;, 17.3&#xb0;, 20.5&#xb0;, 22.6&#xb0;, 23.6&#xb0;, 27.7&#xb0;, and 29.2&#xb0;; and further characterized by a DSC scan showing marked endotherm in the range of 258 to 264&#xb0; C.; and further characterized by a specific IR spectra. The invention further relates to a method of preparing the polymorph by recrystallization from other polymorphic forms of 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine by a procedure comprising the following operations: mixing of 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine with a polar aprotic solvent, preferably with dimethylsulfoxide, and heating to form a saturated solution; cooling of the saturated solution with formation of a turbid solution of 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine; addition of the turbid solution of 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine to a protic solvent, preferably methanol, with separation of a gel-like precipitate; heating of the separated gel-like precipitate in the protic solvent to a boil with formation of a suspension of polymorph E; and cooling of the suspension, isolation and drying of polymorph E.

[object Object]

A method of preparation of N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea of formula (I) with the use of a reaction of 1-(benzo[b]thien-2-yl)-ethanol of formula (II) with hydroxyurea of formula (III) in organic solvents, organic acids, their mixtures or in mixtures thereof with water, being catalyzed by strongly acidic cation exchangers or various hydrogen sulphates. 

Process for the preparation of N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea

The invention deals with a preparation method of salts of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (tizanidine) of formula I, especially tizanidine hydrochloride, comprising preparation of a salt of tizanidine of formula I and a carboxylic acid as an intermediate, from which, after acidification with hydrogen chloride, tizanidine hydrochloride is obtained in a high yield and purity. 

Method for the preparation of tizanidine hydrochloride

A method for preparing 4-[3,5-bis(2-hydroxyphenyl )-[1,2,4]triazol-1-yl]benzoic acid of formula (I) by reaction of 2-(2-hydroxyphenyl)benz[e][1,3]oxazin-4-one of formula (II) with 4-hydrazinobenzoic acid of formula (III) in an organic acid or in a mixture of an organic acid and an organic solvent. 

Method for preparing 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid

A method for the preparation of salts of 2-[2-(4-dibenzo[b,fj[1,4]thiazepin-11-yl-1 -piperazinyl)ethoxy]ethanol (quetiapine) from the quetiapine base and the respective acid, wherein the salt is precipitated from a mixture of solvents, the mixture being either a mixture of an aromatic hydrocarbon and a ketone or ester, or that of an aromatic hydrocarbon, water and a ketone or ester. The salts of quetiapine are purified by partial crystallization, wherein only a part of the salt of quetiapine is dissolved in a Cto Calcohol used.

Methods for the preparation of salts of 2-[2-(4-dibenzo[B,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxyl]ethanol (quetiapine) and for the purification thereof

A process for preparing optically pure enantiomers of R-(&#x2212;)tamsulosin of formiula Ia and S-(+)tamsulosin of formula Ib by resolving racemic tamsulosin of formula I by means of (IR)-(&#x2212;)-camphor-10-sulfonic acid and (1S)-(+)-camphor-10-sulfonic acid, resp., in an environment of organic solvents, water or mixtures thereof.

Process for preparing R- and S-isomers of (R)-5-(2-( (2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide

Growing community of inventors

Hlusovice, Czechia

Pavel Hradil